Naftopidil Powder

Naftopidil antagonizes α₁-adrenoceptors, reducing the corresponding adrenergic responses. Its receptor profile shows a relative preference for α₁D rather than exclusive activity at this subtype.

An original study using cloned human receptors reported the following affinity relationships:

Comparison - Reported relative binding affinity

α₁D versus α₁A：Approximately 3-fold higher affinity for α₁D

α₁D versus α₁B：Approximately 17-fold higher affinity for α₁D

Naftopidil can be used to investigate adrenergically stimulated responses in the prostate, urethra, and related tissues.

An original study compared prostatic pressure and blood-pressure responses in dogs and combined these experiments with cloned human receptor-binding assays. The findings supported investigation of how α₁A and α₁D affinity contributes to tissue-level functional selectivity.

Reduced smooth-muscle tone does not establish a reduction in prostate size. Acute relaxation and long-term tissue growth are distinct endpoints requiring separate assessment.

Isolated-tissue experiments can combine norepinephrine or phenylephrine stimulation with nonadrenergic contraction controls.

Naftopidil research extends beyond urethral smooth muscle to bladder storage reflexes and sensory afferent pathways.

In a rat model of cerebral infarction-associated detrusor overactivity, naftopidil increased bladder capacity. This effect disappeared following resiniferatoxin treatment used to desensitize C-fiber afferents. The investigators proposed involvement of C-fiber-associated pathways in the lumbosacral spinal cord.

These findings represent functional evidence from a specific animal model. They do not independently establish that naftopidil selectively blocks a particular C-fiber ion channel.

A spinal-slice electrophysiology study also reported that 100 μM naftopidil reduced Aδ- and C-fiber-evoked excitatory postsynaptic currents. Because this experiment used a high concentration, interpretation should consider noncanonical effects and comparability with achievable tissue exposure.

Beyond its established receptor pharmacology, naftopidil has been investigated for effects on cell proliferation and cell-cycle regulation.

An original prostate cancer study reported growth inhibition accompanied by G₁-phase arrest:

• In LNCaP cells, p21 and p27 expression increased.
• In PC-3 cells, p21 increased without a corresponding increase in p27.
• Growth inhibition was also reported in a PC-3 xenograft model in nude mice.

Naftopidil contains a chiral center, making it useful for investigating differences in metabolism between enantiomers.

A human in vitro metabolism study identified contributions from multiple CYP enzymes. CYP2C9 and CYP2C19 inhibitors strongly inhibited R(+)-naftopidil metabolism, while inhibitors of several other CYP enzymes produced varying degrees of inhibition.

Consequently, its metabolism should not be reduced to a universal single-enzyme description.